Identification
- Composition (DCI)
- encorafenib
- Manufacturer
- PFIZER MAROC
- ATC code
- L01EC03
- Presentation
- Boite de 42
- Schedule / Reimb.
- A
- Hospital price
- 12793.00 MAD
Indications
L’encorafenib est indiqué : - en association au binimetinib dans le traitement de patients adultes atteints de mélanome non résécable ou métastatique porteur d'une mutation BRAF V600 . en association au cetuximab, dans le traitement de patients adultes atteints de cancer colorectal (CCR) métastatique porteur d’une mutation BRAF V600E, ayant reçu un traitement systémique antérieur.
Find an open pharmacy
On-call pharmacies near you
About BRAFTOVI 75 MG
BRAFTOVI 75 MG is marketed in Morocco by PFIZER MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of BRAFTOVI 75 MG, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about BRAFTOVI 75 MG
Answers to common questions from Moroccan patients about this drug.